Medtronic (MDT) said Thursday evening that the Centers for Medicare & Medicaid Services has issued a proposed national coverage determination for the company's Symplicity Spyral renal denervation system, triggering a 30-day public comment period.

The proposed decision marks a key step toward potential nationwide Medicare coverage for the minimally invasive system, which is designed to treat high blood pressure by delivering radiofrequency energy to overactive nerves near the kidneys, the healthcare technology company said.

The final coverage decision is expected on or before Oct. 8, and until then, coverage for Medicare patients will continue to be determined on a case-by-case basis, the company added.

Shares of Medtronic were slightly higher in recent Friday trading.

Price: 89.82, Change: +0.42, Percent Change: +0.47